Johnson & Johnson
Executive Summary
Nobel laureate Sir James Black elected to board. Black was the principal developer of Inderal (propranolol) and discoverer of the H]2[ antagonists that made possible the development of SmithKline's Tagamet (cimetidine). J&J has a 1987 agreement to fund the James Black Foundation in the U.K.